Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights

Biotech SG&A Expenses: A Decade of Growth and Strategy

__timestampBioCryst Pharmaceuticals, Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 2014746100034916000
Thursday, January 1, 20151304700036949000
Friday, January 1, 20161125300045240000
Sunday, January 1, 20171393300062416000
Monday, January 1, 20182951400081289000
Tuesday, January 1, 201937121000100359000
Wednesday, January 1, 202067929000105326000
Friday, January 1, 2021118818000122356000
Saturday, January 1, 2022159371000152848000
Sunday, January 1, 2023213894000184259000
Loading chart...

Unleashing the power of data

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, both companies have shown significant growth in their SG&A expenses, reflecting their expanding operations and market presence.

BioCryst Pharmaceuticals started with a modest SG&A expense of approximately $7.5 million in 2014, which surged by nearly 2800% to over $213 million by 2023. Meanwhile, Corcept Therapeutics saw its expenses grow from around $35 million to $184 million, marking a 426% increase. This trend highlights the aggressive expansion strategies employed by both companies.

Understanding these financial dynamics provides valuable insights into how these biotech firms allocate resources to support their growth and innovation strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025